Holen Sie sich die Stockscreener-App
9.7142
0.82%
-0.0858
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - Morningstar
ATRA stock shoots up 82% in a month: Here's what you should know - MSN
ATRA DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Atara Biotherapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - New Castle News
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - The Joplin Globe
ATARA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ATRARA (NASDAQ:ATRA) DEADLINE MAY 22nd: Bragar Eagel & - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know - The Globe and Mail
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - PR Newswire
Atara Biotherapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your RightsATRA - PR Newswire
Atara Biotherapeutics CAO sells $22,036 of company stock By Investing.com - Investing.com Canada
Atara Biotherapeutics CEO AnhCo Nguyen sells $47,844 in stock By Investing.com - Investing.com South Africa
Atara Biotherapeutics CEO AnhCo Nguyen sells $47,844 in stock - Investing.com
Atara (ATRA) CEO sells 5,241 shares in automatic tax sale - Stock Titan
Atara Biotherapeutics (ATRA) CAO sells 2,414 shares to cover RSU tax - Stock Titan
ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. ... - Caledonian Record
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages - GlobeNewswire
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Atara Biotherapeutics Raised to Hold From Sell by Freedom Broker - Moomoo
Atara Biotherapeutics Price Target Raised to $10.00/Share From $4.00 by Freedom Broker - Moomoo
ATRA UPCOMING DEADLINE : The Gross Law Firm Alerts Atara Biotherapeutics, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Class Action Litigation Filed by Pomerantz LLP for Investors of Atara Biotherapeutics, Inc. – ATRA - ACCESS Newswire
ATRA Upgraded by Freedom Broker -- Price Target Raised to $10 - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, I - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - lincolnjournal.com
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATARA DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, - GlobeNewswire
[144] Atara Biotherapeutics, Inc. SEC Filing - Stock Titan
Company (NASDAQ: ATRA) RSU Settlement and 2,104-Share Sale - Stock Titan
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire
Freedom Broker upgrades Atara Biotherapeutics stock rating on FDA meeting progress - Investing.com
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit ... - Caledonian Record
Class Action Litigation Filed by Pomerantz LLP Concerning Atara Biotherapeutics, Inc. – ATRA - ACCESS Newswire
Trading Systems Reacting to (ATRA) Volatility - Stock Traders Daily
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action ... - Caledonian Record
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 22, 2026ATRA - The Daily Tribune News
Redmile funds disclose 9.9% Atara Biotherapeutics (ATRA) stake via warrants cap - Stock Titan
ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ATARA DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, - GlobeNewswire
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):